Academic Textbook: The Role of Stem Cells in Treatment of Autoimmune Diseases
Keywords:
Stem Cells, Treatment, Autoimmune DiseasesAbstract
MSCs are a type of pluripotent cell exist in tissues of mesenchymal origin and are responsible for tissue regeneration. MSCs are found by specific surface indicators and their ability to adhere to plastic substrates and develop into adipocytes, osteocytes, and chondrocytes in vitro. MSCs consist of different types of cells, and the most well-known are bone marrow-derived stromal stem cells. Other MSCs include umbilical cord MSCs, adipose-derived stem cells, and amniotic fluid stem cells, which are detected in the stromal vascular fraction of adipose tissue. MSCs are being assessed not only for their ability to regenerate cells but also for their immunomodulatory characteristics, given that they seem to modulate the secretion of lymphocyte-derived cytokines directly. Autologous hematopoietic stem cell transplantation (AHSCT) after immunoablation was known as the suitable IR treatment method in the cases affected by autoimmune diseases.
References
1. Salou M, Elong Ngono A, Garcia A, Michel L, Laplaud DA. [Adaptative immunity and pathophysiology of multiple sclerosis]. Rev Med Interne. 2013;34(8):479-86.
2. Vazirinejad R, Ahmadi Z, Kazemi Arababadi M, Hassanshahi G, Kennedy D. The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Neuroimmunomodulation. 2014;21(6):322-30.
3. Nicholas R, Young C, Friede T. Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. Expert Opin Drug Saf. 2010;9(6):905-15.
4. Celarain N, Tomas-Roig J. Changes in Deoxyribonucleic Acid Methylation Contribute to the Pathophysiology of Multiple Sclerosis. Front Genet. 2019;10:1138.
5. Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Prefer Adherence. 2022;16:1307-19.
6. Buscarinu MC, Fornasiero A, Romano S, Ferraldeschi M, Mechelli R, Reniè R, et al. The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. Front Immunol. 2019;10:1916.
7. Adamczyk-Sowa M, Medrek A, Madej P, Michlicka W, Dobrakowski P. Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology? Journal of immunology research. 2017;2017:7904821.
8. Dolcetti E, Bruno A, Guadalupi L, Rizzo FR, Musella A, Gentile A, et al. Emerging Role of Extracellular Vesicles in the Pathophysiology of Multiple Sclerosis. International journal of molecular sciences. 2020;21(19).
9. Minagar A, Maghzi AH, McGee JC, Alexander JS. Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy. Neurol Res. 2012;34(8):738-45.
10. Oh J, Bar-Or A. Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nat Rev Neurol. 2022.
11. Groen K, Maltby VE, Sanders KA, Scott RJ, Tajouri L, Lechner-Scott J. Erythrocytes in multiple sclerosis - forgotten contributors to the pathophysiology? Mult Scler J Exp Transl Clin. 2016;2:2055217316649981.
12. Nazeri A, Heydarpour P, Sadaghiani S, Sahraian MA, Burkly LC, Bar-Or A. A further TWEAK to multiple sclerosis pathophysiology. Mol Neurobiol. 2014;49(1):78-87.
13. Arneth BM. Impact of B cells to the pathophysiology of multiple sclerosis. J Neuroinflammation. 2019;16(1):128.
14. Zostawa J, Adamczyk J, Sowa P, Adamczyk-Sowa M. The influence of sodium on pathophysiology of multiple sclerosis. Neurol Sci. 2017;38(3):389-98.
15. Camara-Lemarroy CR, Metz L, Meddings JB, Sharkey KA, Wee Yong V. The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. Brain. 2018;141(7):1900-16.
16. Backner Y, Levin N. Keep Your Eyes Wide Open: On Visual- and Vision-Related Measurements to Better Understand Multiple Sclerosis Pathophysiology. J Neuroophthalmol. 2018;38(1):85-90.
17. Teuber-Hanselmann S, Meinl E, Junker A. MicroRNAs in gray and white matter multiple sclerosis lesions: impact on pathophysiology. J Pathol. 2020;250(5):496-509.
18. Lassmann H. Models of multiple sclerosis: new insights into pathophysiology and repair. Curr Opin Neurol. 2008;21(3):242-7.
19. Filippi M, Rocca MA. MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy. AJNR Am J Neuroradiol. 2010;31(7):1171-7.
20. Berger T, Reindl M. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J Neurol Sci. 2007;259(1-2):21-6.
21. Adamczyk B, Adamczyk-Sowa M. New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis. Oxid Med Cell Longev. 2016;2016:1973834.
22. Khorramdelazad H, Bagheri V, Hassanshahi G, Zeinali M, Vakilian A. New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis. J Neuroimmunol. 2016;290:70-5.
23. Adamczyk B, Niedziela N, Adamczyk-Sowa M. Novel Approaches of Oxidative Stress Mechanisms in the Multiple Sclerosis Pathophysiology and Therapy. In: Zagon IS, McLaughlin PJ, editors. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Brisbane (AU): Codon Publications
Copyright: The Authors.; 2017.
24. Gupta S, Ahsan I, Mahfooz N, Abdelhamid N, Ramanathan M, Weinstock-Guttman B. Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs. 2014;28(8):731-42.
25. Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13(1):320.
26. Racke MK, Frohman EM, Frohman T. Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes. Front Neurol. 2021;12:799698.
27. Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008;255 Suppl 6:2-6.
28. Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124(2):75-84.
29. Junker A. Pathophysiology of translational regulation by microRNAs in multiple sclerosis. FEBS Lett. 2011;585(23):3738-46.
30. Rottoli M, La Gioia S, Frigeni B, Barcella V. Pathophysiology, assessment and management of multiple sclerosis fatigue: an update. Expert Rev Neurother. 2017;17(4):373-9.
31. Haas J. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update. Expert Rev Neurother. 2011;11(4 Suppl):3-8.
32. Zéphir H. Progress in understanding the pathophysiology of multiple sclerosis. Rev Neurol (Paris). 2018;174(6):358-63.
33. Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18(12):905-22.
34. Morris G, Stubbs B, Köhler CA, Walder K, Slyepchenko A, Berk M, et al. The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. Sleep Med Rev. 2018;41:255-65.
35. Niino M. [Recent prognosis on etiology and pathophysiology of multiple sclerosis]. Nihon Rinsho. 2013;71(5):807-10.
36. Lorincz B, Jury EC, Vrablik M, Ramanathan M, Uher T. The role of cholesterol metabolism in multiple sclerosis: From molecular pathophysiology to radiological and clinical disease activity. Autoimmun Rev. 2022;21(6):103088.
37. Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural regeneration research. 2019;14(3):373-86.
38. Filippi M, Rocca MA. The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology. Acta Neurol Belg. 2011;111(2):89-98.
39. Alavi MS, Karimi G, Roohbakhsh A. The role of orphan G protein-coupled receptors in the pathophysiology of multiple sclerosis: A review. Life Sci. 2019;224:33-40.
40. Kelley BJ, Rodriguez M. Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs. 2009;23(10):805-15.
41. Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10(1):51-66.
42. Collongues N, Patte-Mensah C, De Seze J, Mensah-Nyagan AG, Derfuss T. Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics. Expert Rev Neurother. 2018;18(6):515-22.
43. Di Benedetto P, Delneri C, Biasutti E, Bragadin LM, Giorgini T. Vesicourethral dysfunction in multiple sclerosis. Initial assessment based on lower urinary tract symptoms and their pathophysiology. Neurol Sci. 2008;29 Suppl 4:S348-51.
44. Santhosh P, George M. Annular atrophic lichen planus: a review of the literature. Int J Dermatol. 2022.
45. González-Moles M, Ramos-García P, Warnakulasuriya S. An appraisal of highest quality studies reporting malignant transformation of oral lichen planus based on a systematic review. Oral Dis. 2021;27(8):1908-18.
46. Bansal D, Kamboj M, Anand R, Pandiar D, Narwal A, Sivakumar N, et al. Association of childhood vaccination with pediatric lichen planus: A systematic review. Int J Dermatol. 2021.
47. De Porras-Carrique T, Ramos-García P, Aguilar-Diosdado M, Warnakulasuriya S, González-Moles M. Autoimmune disorders in oral lichen planus: A systematic review and meta-analysis. Oral Dis. 2022.
48. Merio L, Tounkara TM, Battesti G, Cordoliani F, Arsouze A, Bagot M, et al. Blaschko-linear lichen planus of the face: A retrospective study of 6 cases and a literature review. Ann Dermatol Venereol. 2022;149(2):112-8.
49. Sears S, Daftary K, Burch A, Todd P. A case of annular atrophic lichen planus in a child and review of the literature. Pediatr Dermatol. 2021;38(5):1283-7.
50. Papara C, Danescu S, Sitaru C, Baican A. Challenges and pitfalls between lichen planus pemphigoides and bullous lichen planus. Australas J Dermatol. 2022;63(2):165-71.
51. Li K, He W, Hua H. Characteristics of the psychopathological status of oral lichen planus: a systematic review and meta-analysis. Aust Dent J. 2022.
52. Shikha, Gupta S, Mahajan A, Ambika, Garg R, Ghosh S. Childhood oral lichen planus: a case series with review of literature. Eur Arch Paediatr Dent. 2022;23(2):341-53.
53. Jacobs JW, Jr., Kukreja K, Camisa C, Richter JE. Demystifying Esophageal Lichen Planus: A Comprehensive Review of a Rare Disease You Will See in Practice. Am J Gastroenterol. 2022;117(1):70-7.
54. Gururaj N, Hasinidevi P, Janani V, Divynadaniel T. Diagnosis and management of oral lichen planus - Review. J Oral Maxillofac Pathol. 2021;25(3):383-93.
55. Nunes GP, Pirovani BO, Nunes LP, Silva ANA, Morábito M, Nunes-Júnior NA, et al. Does oral lichen planus aggravate the state of periodontal disease? A systematic review and meta-analysis. Clin Oral Investig. 2022;26(4):3357-71.
56. González-Moles M, Warnakulasuriya S, González-Ruiz I, Ayén Á, González-Ruiz L, Ruiz-Ávila I, et al. Dysplasia in oral lichen planus: relevance, controversies and challenges. A position paper. Med Oral Patol Oral Cir Bucal. 2021;26(4):e541-e8.
57. Waingade M, Medikeri RS, Rathod P. Effectiveness of methylene blue photosensitizers compared to that of corticosteroids in the management of oral lichen planus: a systematic review and meta-analysis. J Dent Anesth Pain Med. 2022;22(3):175-86.
58. Łukaszewska-Kuska M, Ślebioda Z, Dorocka-Bobkowska B. The effectiveness of topical forms of dexamethasone in the treatment of oral lichen planus- A systematic review. Oral Dis. 2021.
59. Del Vecchio A, Palaia G, Grassotti B, Tenore G, Ciolfi C, Podda G, et al. Effects of laser photobiomodulation in the management of oral lichen planus: a literature review. Clin Ter. 2021;172(5):467-83.
60. Su Z, Hu J, Cheng B, Tao X. Efficacy and safety of topical administration of tacrolimus in oral lichen planus: An updated systematic review and meta-analysis of randomized controlled trials. J Oral Pathol Med. 2022;51(1):63-73.
61. da Silva EL, de Lima TB, Rados PV, Visioli F. Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis. Clin Oral Investig. 2021;25(9):5149-69.
62. Seif S, Afra N, Dadgar E, Enteghad S, Argani P, Aghdasi N, et al. The expression of salivary microRNAs in oral lichen planus: Searching for a prognostic biomarker. Pathol Res Pract. 2022;234:153923.
63. Karimova M, Moyes D, Ide M, Setterfield JF. The human microbiome in immunobullous disorders and lichen planus. Clin Exp Dermatol. 2022;47(3):522-8.
64. El-Howati A, Thornhill MH, Colley HE, Murdoch C. Immune mechanisms in oral lichen planus. Oral Dis. 2022.
65. Anitua E, Alkhraisat MH, Piñas L, Torre A, Eguia A. Implant-prosthetic treatment in patients with oral lichen planus: A systematic review. Spec Care Dentist. 2022;42(1):60-72.
66. Boch K, Langan EA, Kridin K, Zillikens D, Ludwig RJ, Bieber K. Lichen Planus. Front Med (Lausanne). 2021;8:737813.
67. Pogorzelska-Antkowiak A. Lichen planus -like keratosis: what do we know about? Clin Exp Dermatol. 2022.
68. Boyle MM, Ashi S, Puiu T, Reimer D, Sokumbi O, Soltani K, et al. Lichen Planus Pemphigoides Associated With PD-1 and PD-L1 Inhibitors: A Case Series and Review of the Literature. Am J Dermatopathol. 2022;44(5):360-7.
69. Shah RR, Bhate C, Hernandez A, Ho CH. Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab. Dermatol Ther. 2022;35(5):e15432.
70. Moosavi MS, Tavakol F. Literature review of cancer stem cells in oral lichen planus: a premalignant lesion. Stem Cell Investig. 2021;8:25.
71. Ghazi N, Khorasanchi M. Markers associated with malignant transformation of oral lichen planus: A review article. Arch Oral Biol. 2021;127:105158.
72. Grover C, Kharghoria G, Baran R. Nail lichen planus: A review of clinical presentation, diagnosis and therapy. Ann Dermatol Venereol. 2022.
73. Ruiz-Lozano RE, Hernández-Camarena JC, Valdez-Garcia JE, Roman-Zamudio M, Herrera-Rodriguez MI, Andrade-Carrillo D, et al. Ocular involvement and complications of lichen planus, lichen planus pigmentosus, and lichen planopilaris: A comprehensive review. Dermatol Ther. 2021;34(6):e15137.
74. Villa TG, Sánchez-Pérez Á, Sieiro C. Oral lichen planus: a microbiologist point of view. Int Microbiol. 2021;24(3):275-89.
75. Jung W, Jang S. Oral Microbiome Research on Oral Lichen Planus: Current Findings and Perspectives. Biology (Basel). 2022;11(5).
76. Merhy R, Sarkis AS, Assaf J, Afiouni R, Zeinaty P, Kechichian E, et al. Pediatric lichen planus: a systematic review of 985 published cases. Int J Dermatol. 2022;61(4):416-21.
77. Husein-ElAhmed H, Steinhoff M. Potential role of INTERLEUKIN-17 in the pathogenesis of oral lichen planus: a systematic review with META-analysis. J Eur Acad Dermatol Venereol. 2022.
78. Zanetta P, Ormelli M, Amoruso A, Pane M, Azzimonti B, Squarzanti DF. Probiotics as Potential Biological Immunomodulators in the Management of Oral Lichen Planus: What's New? International journal of molecular sciences. 2022;23(7).
79. Leis M, Singh A, Li C, Ahluwalia R, Fleming P, Lynde CW. Risk of Vulvar Squamous Cell Carcinoma in Lichen Sclerosus and Lichen Planus: A Systematic Review. J Obstet Gynaecol Can. 2022;44(2):182-92.
80. Sushanthi LC, Ramani P, Ramasubramanian A, Gheena S, Krishnan RP. Serum Cortisol Levels in Lichen Planus: A Systematic Review with Meta-Analysis. Indian J Dermatol. 2021;66(6):654-9.
81. Marnach ML, Torgerson RR. Therapeutic Interventions for Challenging Cases of Vulvar Lichen Sclerosus and Lichen Planus. Obstet Gynecol. 2021;138(3):374-8.
82. Guarneri F, Bertino L, Pioggia G, Casciaro M, Gangemi S. Therapies with Antioxidant Potential in Psoriasis, Vitiligo, and Lichen Planus. Antioxidants (Basel). 2021;10(7).
83. Offen E, Allison JR. What is the malignant transformation potential of oral lichen planus? Evid Based Dent. 2022;23(1):36-7.
84. Ruiyang B, Panayi A, Ruifang W, Peng Z, Siqi F. Adiponectin in psoriasis and its comorbidities: a review. Lipids Health Dis. 2021;20(1):87.
85. Łuczaj W, Gęgotek A, Skrzydlewska E. Analytical approaches to assess metabolic changes in psoriasis. J Pharm Biomed Anal. 2021;205:114359.
86. Schön MP, Manzke V, Erpenbeck L. Animal models of psoriasis-highlights and drawbacks. J Allergy Clin Immunol. 2021;147(2):439-55.
87. Zwain A, Aldiwani M, Taqi H. The Association Between Psoriasis and Cardiovascular Diseases. Eur Cardiol. 2021;16:e19.
88. Hedemann TL, Liu X, Kang CN, Husain MI. Associations between psoriasis and mental illness: an update for clinicians. Gen Hosp Psychiatry. 2022;75:30-7.
89. Aghamajidi A, Raoufi E, Parsamanesh G, Jalili A, Salehi-Shadkami M, Mehrali M, et al. The attentive focus on T cell-mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo. Scand J Immunol. 2021;93(4):e13000.
90. Uppala R, Tsoi LC, Harms PW, Wang B, Billi AC, Maverakis E, et al. "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307-17.
91. Freitas E, Blauvelt A, Torres T. Bimekizumab for the Treatment of Psoriasis. Drugs. 2021;81(15):1751-62.
92. Singh R, Koppu S, Perche PO, Feldman SR. The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. International journal of molecular sciences. 2021;22(23).
93. Lytvyn Y, Sachdeva M, Mufti A, Yeung J. Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour. Drugs Context. 2022;11.
94. Romiti R, Hirayama A, Arnone M, Magalhães RF. Generalized pustular psoriasis (von Zumbusch). An Bras Dermatol. 2022;97(1):63-74.
95. Sarama R, Matharu PK, Abduldaiem Y, Corrêa MP, Gil CD, Greco KV. In Vitro Disease Models for Understanding Psoriasis and Atopic Dermatitis. Front Bioeng Biotechnol. 2022;10:803218.
96. Kölliker Frers R, Otero-Losada M, Kobiec T, Herrera MI, Udovin L, Kusnier CF, et al. Interleukin-1 Links Autoimmune and Autoinflammatory Pathophysiology in Mixed-Pattern Psoriasis. Mediators Inflamm. 2021;2021:2503378.
97. Dobrică EC, Cozma MA, Găman MA, Voiculescu VM, Găman AM. The Involvement of Oxidative Stress in Psoriasis: A Systematic Review. Antioxidants (Basel). 2022;11(2).
98. Bellinato F, Gisondi P, Girolomoni G. Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. Biologics. 2021;15:247-53.
99. Bugaut H, Aractingi S. Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies. Front Immunol. 2021;12:621956.
100. Mascarenhas-Melo F, Carvalho A, Gonçalves MBS, Paiva-Santos AC, Veiga F. Nanocarriers for the topical treatment of psoriasis - pathophysiology, conventional treatments, nanotechnology, regulatory and toxicology. Eur J Pharm Biopharm. 2022;176:95-107.
101. Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network? J Dtsch Dermatol Ges. 2021;19(4):517-28.
102. Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13-9.
103. Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: A review. J Dermatol. 2021;48(6):722-31.
104. Lin X, Meng X, Song Z, Lin J. Peroxisome proliferator-activator receptor γ and psoriasis, molecular and cellular biochemistry. Mol Cell Biochem. 2022;477(7):1905-20.
105. Kahremany S, Hofmann L, Harari M, Gruzman A, Cohen G. Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives. Pharmacol Rep. 2021;73(2):443-53.
106. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet (London, England). 2021;397(10281):1301-15.
107. Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Frątczak A, Kiss N. Psoriasis and Gut Microbiome-Current State of Art. International journal of molecular sciences. 2021;22(9).
108. Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797-806.
109. Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2021;9(11).
110. Medovic MV, Jakovljevic VL, Zivkovic VI, Jeremic NS, Jeremic JN, Bolevich SB, et al. Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches. Oxid Med Cell Longev. 2022;2022:2249834.
111. Nosbaum A, Dahel K, Goujon C, Nicolas JF, Mengeaud V, Vocanson M. Psoriasis is a disease of the entire skin: non-lesional skin displays a prepsoriasis phenotype. Eur J Dermatol. 2021;31(2):143-54.
112. Petit RG, Cano A, Ortiz A, Espina M, Prat J, Muñoz M, et al. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. International journal of molecular sciences. 2021;22(9).
113. Summa C, Patel P, Kesselman MM, Demory Beckler M. Psoriasis: To Vaccinate or Not to Vaccinate? Cureus. 2021;13(6):e15860.
114. Woźniak E, Owczarczyk-Saczonek A, Placek W. Psychological Stress, Mast Cells, and Psoriasis-Is There Any Relationship? International journal of molecular sciences. 2021;22(24).
115. Menter A, Van Voorhees AS, Hsu S. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Dermatol Ther (Heidelb). 2021;11(6):1917-29.
116. Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular Psoriasis: From Pathophysiology to Treatment. Biomedicines. 2021;9(12).
117. Ion A, Dorobanțu AM, Popa LG, Mihai MM, Orzan OA. Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases. Biology (Basel). 2022;11(6).
118. Visser MJE, Tarr G, Pretorius E. Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk. Front Immunol. 2021;12:688861.
119. Li N, Qin Y, Dai D, Wang P, Shi M, Gao J, et al. Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis. Front Bioeng Biotechnol. 2021;9:804415.
120. Timis TL, Florian IA, Vesa SC, Orasan RI. Treatment of psoriasis - unburdened by fear during SARS-CoV2 menace. J Dermatolog Treat. 2022;33(2):662-5.
121. Filippa MG, Tektonidou MG, Mantzou A, Kaltsas GA, Chrousos GP, Sfikakis PP, et al. Adrenocortical dysfunction in rheumatoid arthritis: Α narrative review and future directions. Eur J Clin Invest. 2022;52(1):e13635.
122. Monu, Agnihotri P, Biswas S. AGE/Non-AGE Glycation: An Important Event in Rheumatoid Arthritis Pathophysiology. Inflammation. 2022;45(2):477-96.
123. Kessler J, Totoson P, Devaux S, Moretto J, Wendling D, Demougeot C. Animal models to study pathogenesis and treatments of cardiac disorders in rheumatoid arthritis: Advances and challenges for clinical translation. Pharmacol Res. 2021;170:105494.
124. Zhao J, Jiang P, Guo S, Schrodi SJ, He D. Apoptosis, Autophagy, NETosis, Necroptosis, and Pyroptosis Mediated Programmed Cell Death as Targets for Innovative Therapy in Rheumatoid Arthritis. Front Immunol. 2021;12:809806.
125. Rose J. Autoimmune Connective Tissue Diseases: Systemic Lupus Erythematosus and Rheumatoid Arthritis. Emerg Med Clin North Am. 2022;40(1):179-91.
126. Trzeciak P, Herbet M, Dudka J. Common Factors of Alzheimer's Disease and Rheumatoid Arthritis-Pathomechanism and Treatment. Molecules. 2021;26(19).
127. Wenger A, Calabrese P. Comparing underlying mechanisms of depression in multiple sclerosis and rheumatoid arthritis. J Integr Neurosci. 2021;20(3):765-76.
128. Unterberger S, Davies KA, Rambhatla SB, Sacre S. Contribution of Toll-Like Receptors and the NLRP3 Inflammasome in Rheumatoid Arthritis Pathophysiology. Immunotargets Ther. 2021;10:285-98.
129. Nattagh-Eshtivani E, Pahlavani N, Ranjbar G, Gholizadeh Navashenaq J, Salehi-Sahlabadi A, Mahmudiono T, et al. Does propolis have any effect on rheumatoid arthritis? A review study. Food Sci Nutr. 2022;10(4):1003-20.
130. Qamar N, John P, Bhatti A. Emerging role of selenium in treatment of rheumatoid arthritis: An insight on its antioxidant properties. J Trace Elem Med Biol. 2021;66:126737.
131. Kraus SE, Lee E. Engineering approaches to investigate the roles of lymphatics vessels in rheumatoid arthritis. Microcirculation. 2022:e12769.
132. Singh A, Behl T, Sehgal A, Singh S, Sharma N, Mani V, et al. Exploring the therapeutic promise of targeting Rho kinase in rheumatoid arthritis. Inflammopharmacology. 2021;29(6):1641-51.
133. Anang DC, Balzaretti G, van Kampen A, de Vries N, Klarenbeek PL. The Germinal Center Milieu in Rheumatoid Arthritis: The Immunological Drummer or Dancer? International journal of molecular sciences. 2021;22(19).
134. Cutolo M, Soldano S, Sulli A, Smith V, Gotelli E. Influence of Seasonal Vitamin D Changes on Clinical Manifestations of Rheumatoid Arthritis and Systemic Sclerosis. Front Immunol. 2021;12:683665.
135. Bozzalla-Cassione E, Grignaschi S, Xoxi B, Luvaro T, Greco MI, Mazzucchelli I, et al. Insights Into the Concept of Rheumatoid Arthritis Flare. Front Med (Lausanne). 2022;9:852220.
136. Gadeval A, Chaudhari S, Bollampally SP, Polaka S, Kalyane D, Sengupta P, et al. Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis. Drug Discov Today. 2021;26(10):2315-28.
137. Kim M, Choe YH, Lee SI. Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research. Immune Netw. 2022;22(1):e8.
138. Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021;10(11).
139. Zhao J, Guo S, Schrodi SJ, He D. Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications. Front Immunol. 2021;12:790122.
140. Katturajan R, S V, Rasool M, Evan Prince S. Molecular toxicity of methotrexate in rheumatoid arthritis treatment: A novel perspective and therapeutic implications. Toxicology. 2021;461:152909.
141. Park E, Griffin J, Bathon JM. Myocardial Dysfunction and Heart Failure in Rheumatoid Arthritis. Arthritis Rheumatol. 2022;74(2):184-99.
142. Rahimizadeh P, Rezaieyazdi Z, Behzadi F, Hajizade A, Lim SI. Nanotechnology as a promising platform for rheumatoid arthritis management: Diagnosis, treatment, and treatment monitoring. Int J Pharm. 2021;609:121137.
143. Florescu A, Gherghina FL, Mușetescu AE, Pădureanu V, Roșu A, Florescu MM, et al. Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review. Biomedicines. 2022;10(6).
144. Nooreen R, Nene S, Jain H, Prasannanjaneyulu V, Chitlangya P, Otavi S, et al. Polymer nanotherapeutics: A versatile platform for effective rheumatoid arthritis therapy. J Control Release. 2022;348:397-419.
145. Yamasaki S, Nakashima M, Ida H. Possible Roles of tRNA Fragments, as New Regulatory ncRNAs, in the Pathogenesis of Rheumatoid Arthritis. International journal of molecular sciences. 2021;22(17).
146. Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C. Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Front Immunol. 2021;12:686155.
147. Liang M, Matteson EL, Abril A, Distler JHW. The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease. Ther Adv Musculoskelet Dis. 2022;14:1759720x221074457.
148. Kaur G, Sharma A, Bhatnagar A. Role of oxidative stress in pathophysiology of rheumatoid arthritis: insights into NRF2-KEAP1 signalling. Autoimmunity. 2021;54(7):385-97.
149. Moreira FRC, de Oliveira TA, Ramos NE, Abreu MAD, Simões ESAC. The role of renin angiotensin system in the pathophysiology of rheumatoid arthritis. Mol Biol Rep. 2021;48(9):6619-29.
150. Wang Y, Chen S, Du K, Liang C, Wang S, Owusu Boadi E, et al. Traditional herbal medicine: Therapeutic potential in rheumatoid arthritis. J Ethnopharmacol. 2021;279:114368.
151. Shah P, Siddique A, Thakkar A, Gharat S, Godad A, Kale P, et al. An update on novel therapeutic intervention in Rheumatoid arthritis. Int Immunopharmacol. 2022;109:108794.
152. Truong A, Zaghiyan K, Fleshner P. Anorectal Crohn's Disease. Surg Clin North Am. 2019;99(6):1151-62.
153. Minordi LM, Larosa L, Papa A, Bordonaro V, Lopetuso L, Holleran G, et al. Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations. J Gastrointestin Liver Dis. 2019;28:213-24.
154. Kong N, Gao C, Xu M, Gao X. Changes in the anterior cingulate cortex in Crohn's disease: A neuroimaging perspective. Brain Behav. 2021;11(3):e02003.
155. Aksan A, Farrag K, Blumenstein I, Schröder O, Dignass AU, Stein J. Chronic intestinal failure and short bowel syndrome in Crohn's disease. World J Gastroenterol. 2021;27(24):3440-65.
156. Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn's disease. Nature reviews Disease primers. 2020;6(1):22.
157. Qu C, Cao J, Liu K, Tan B, Zhu C, Li K, et al. Crohn's Disease Complicated With Extensive Thrombosis of Limbs and Mesenteric Arteries: A Case Report and Literature Review. Ann Vasc Surg. 2019;58:382.e15-.e19.
158. Veauthier B, Hornecker JR. Crohn's Disease: Diagnosis and Management. Am Fam Physician. 2018;98(11):661-9.
159. Meng ZW, Baumgart DC. Darvadstrocel for the treatment of perianal fistulas in Crohn's disease. Expert Rev Gastroenterol Hepatol. 2020;14(6):405-10.
160. Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, et al. Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis. J Gastroenterol. 2020;55(7):667-78.
161. Popa SL, Pop C, Dumitrascu DL. Diet Advice for Crohn's Disease: FODMAP and Beyond. Nutrients. 2020;12(12).
162. Brennan GT, Ha I, Hogan C, Nguyen E, Jamal MM, Bechtold ML, et al. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(9):997-1002.
163. Caparrós E, Wiest R, Scharl M, Rogler G, Gutiérrez Casbas A, Yilmaz B, et al. Dysbiotic microbiota interactions in Crohn's disease. Gut Microbes. 2021;13(1):1949096.
164. Hansen T, Duerksen DR. Enteral Nutrition in the Management of Pediatric and Adult Crohn's Disease. Nutrients. 2018;10(5).
165. Miyoshi J, Sofia MA, Pierre JF. The evidence for fungus in Crohn's disease pathogenesis. Clin J Gastroenterol. 2018;11(6):449-56.
166. Capriati T, Bizzarri C, Dilillo A, Nobili V, Oliva S, Diamanti A. Growth failure in Crohn's disease children: may the first treatment have a role? Expert Rev Clin Immunol. 2019;15(1):97-104.
167. Brusaferro A, Cavalli E, Farinelli E, Cozzali R, Principi N, Esposito S. Gut dysbiosis and paediatric Crohn's disease. J Infect. 2019;78(1):1-7.
168. Iliopoulou L, Kollias G. Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment. Mucosal Immunol. 2022;15(1):10-26.
169. Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, et al. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018;155(1):76-87.
170. Ma C, Parker CE, Nguyen TM, Khanna R, Feagan BG, Jairath V. Identifying Outcomes in Clinical Trials of Fistulizing Crohn's Disease for the Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2019;17(9):1904-8.
171. Vuyyuru SK, Kedia S, Sahu P, Ahuja V. Immune-mediated inflammatory diseases of the gastrointestinal tract: Beyond Crohn's disease and ulcerative colitis. JGH Open. 2022;6(2):100-11.
172. Lopetuso LR, Napoli M, Rizzatti G, Gasbarrini A. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease. Expert Opin Investig Drugs. 2018;27(6):543-51.
173. Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol. 2021;18(8):544-58.
174. Cho CW, You MW, Oh CH, Lee CK, Moon SK. Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. Gut Liver. 2022;16(2):157-70.
175. Grimstad T, Carlsen A, Karlsen LN. Medical management of fistulising Crohn's disease. Tidsskr Nor Laegeforen. 2019;139(1).
176. Mao R, Kurada S, Gordon IO, Baker ME, Gandhi N, McDonald C, et al. The Mesenteric Fat and Intestinal Muscle Interface: Creeping Fat Influencing Stricture Formation in Crohn's Disease. Inflamm Bowel Dis. 2019;25(3):421-6.
177. Rivera ED, Coffey JC, Walsh D, Ehrenpreis ED. The Mesentery, Systemic Inflammation, and Crohn's Disease. Inflamm Bowel Dis. 2019;25(2):226-34.
178. Fernández-Ponce C, Navarro Quiroz R, Díaz Perez A, Aroca Martinez G, Cadena Bonfanti A, Acosta Hoyos A, et al. MicroRNAs overexpressed in Crohn's disease and their interactions with mechanisms of epigenetic regulation explain novel aspects of Crohn's disease pathogenesis. Clin Epigenetics. 2021;13(1):39.
179. Hayashi Y, Nakase H. The Molecular Mechanisms of Intestinal Inflammation and Fibrosis in Crohn's Disease. Front Physiol. 2022;13:845078.
180. Pochard C, Coquenlorge S, Freyssinet M, Naveilhan P, Bourreille A, Neunlist M, et al. The multiple faces of inflammatory enteric glial cells: is Crohn's disease a gliopathy? Am J Physiol Gastrointest Liver Physiol. 2018;315(1):G1-g11.
181. Blagov A, Zhigmitova EB, Sazonova MA, Mikhaleva LM, Kalmykov V, Shakhpazyan NK, et al. Novel Models of Crohn's Disease Pathogenesis Associated with the Occurrence of Mitochondrial Dysfunction in Intestinal Cells. International journal of molecular sciences. 2022;23(9).
182. Sandall AM, Wall CL, Lomer MCE. Nutrition Assessment in Crohn's Disease using Anthropometric, Biochemical, and Dietary Indexes: A Narrative Review. J Acad Nutr Diet. 2020;120(4):624-40.
183. Takenaka K, Kitazume Y, Fujii T, Tsuchiya K, Watanabe M, Ohtsuka K. Objective evaluation for treat to target in Crohn's disease. J Gastroenterol. 2020;55(6):579-87.
184. Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, et al. Pathophysiology of Crohn's disease inflammation and recurrence. Biol Direct. 2020;15(1):23.
185. Mutanen A, Pakarinen MP. Perianal Crohn's Disease in Children and Adolescents. Eur J Pediatr Surg. 2020;30(5):395-400.
186. Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, et al. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs. 2018;27(7):623-9.
187. Bushara O, Escobar DJ, Weinberg SE, Sun L, Liao J, Yang GY. The Possible Pathogenic Role of IgG4-Producing Plasmablasts in Stricturing Crohn's Disease. Pathobiology. 2022:1-11.
188. Wolford DD, Fichera A. Prophylaxis of Crohn's disease recurrence: A surgeon's perspective. Ann Gastroenterol Surg. 2020;4(5):514-20.
189. Agrawal G, Aitken J, Hamblin H, Collins M, Borody TJ. Putting Crohn's on the MAP: Five Common Questions on the Contribution of Mycobacterium avium subspecies paratuberculosis to the Pathophysiology of Crohn's Disease. Dig Dis Sci. 2021;66(2):348-58.
190. Tozer PJ, Lung P, Lobo AJ, Sebastian S, Brown SR, Hart AL, et al. Review article: pathogenesis of Crohn's perianal fistula-understanding factors impacting on success and failure of treatment strategies. Aliment Pharmacol Ther. 2018;48(3):260-9.
191. Zielińska A, Siwiński P, Sobolewska-Włodarczyk A, Wiśniewska-Jarosińska M, Fichna J, Włodarczyk M. The role of adipose tissue in the pathogenesis of Crohn's disease. Pharmacol Rep. 2019;71(1):105-11.
192. Piotrowska M, Binienda A, Fichna J. The role of fatty acids in Crohn's disease pathophysiology - An overview. Mol Cell Endocrinol. 2021;538:111448.
193. Sensi B, Siragusa L, Efrati C, Petagna L, Franceschilli M, Bellato V, et al. The Role of Inflammation in Crohn's Disease Recurrence after Surgical Treatment. Journal of immunology research. 2020;2020:8846982.
194. Fichera A, Schlottmann F, Krane M, Bernier G, Lange E. Role of surgery in the management of Crohn's disease. Curr Probl Surg. 2018;55(5):162-87.
195. Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn's disease. Expert Opin Drug Saf. 2019;18(5):357-67.
196. Nakase H, Matsumoto T, Watanabe K, Hisamatsu T. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. J Gastroenterol. 2020;55(9):824-32.
197. Dulai PS, Singh S, Vande Casteele N, Boland BS, Rivera-Nieves J, Ernst PB, et al. Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? Clin Gastroenterol Hepatol. 2019;17(13):2634-43.
198. Crespi M, Dulbecco P, De Ceglie A, Conio M. Strictures in Crohn's Disease: From Pathophysiology to Treatment. Dig Dis Sci. 2020;65(7):1904-16.
199. Ma C, Jairath V, Click B, Hirota SA, Lu C, Parker CE, et al. Targeting anti-fibrotic pathways in Crohn's disease - The final frontier? Best Pract Res Clin Gastroenterol. 2019;38-39:101603.
200. Liu M, Lin X, Wang L, He Y, Chen M, Mao R. Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review. J Int Med Res. 2019;47(5):2228-33.
201. Pai RK, Jairath V. What is the role of histopathology in the evaluation of disease activity in Crohn's disease? Best Pract Res Clin Gastroenterol. 2019;38-39:101601.
202. Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, et al. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol. 2021;33(8):1082-90.
203. Buscail E, Le Cosquer G, Gross F, Lebrin M, Bugarel L, Deraison C, et al. Adipose-Derived Stem Cells in the Treatment of Perianal Fistulas in Crohn's Disease: Rationale, Clinical Results and Perspectives. International journal of molecular sciences. 2021;22(18).
204. Nazari H, Naei VY, Tabasi AH, Badripour A, Akbari Asbagh R, Keramati MR, et al. Advanced Regenerative Medicine Strategies for Treatment of Perianal Fistula in Crohn's Disease. Inflamm Bowel Dis. 2022;28(1):133-42.
205. Vasudevan A, Bruining DH, Loftus EV, Jr., Faubion W, Ehman EC, Raffals L. Approach to medical therapy in perianal Crohn's disease. World J Gastroenterol. 2021;27(25):3693-704.
206. Włodarczyk M, Czerwińska K, Włodarczyk J, Fichna J, Dziki A, Dziki Ł. Current Overview on the Use of Mesenchymal Stem Cells for Perianal Fistula Treatment in Patients with Crohn's Disease. Life (Basel). 2021;11(11).
207. Chavoshi M, Mirshahvalad SA, Kasaeian A, Djalalinia S, Kolahdoozan S, Radmard AR. Diagnostic Accuracy of Magnetic Resonance Enterography in the Evaluation of Colonic Abnormalities in Crohn's Disease: A Systematic Review and Meta-Analysis. Acad Radiol. 2021;28 Suppl 1:S192-s202.
208. Inomata Y, Kuroha M, Handa T, Shimoyama Y, Moroi R, Shiga H, et al. Long-term endoscopic remission in Crohn's disease after allogeneic hematopoietic stem cell transplantation for diffuse large B cell lymphoma: case report and literature review. Clin J Gastroenterol. 2021;14(4):1108-14.
209. Gallo G, Tiesi V, Fulginiti S, De Paola G, Vescio G, Sammarco G. Mesenchymal Stromal Cell Therapy in the Management of Perianal Fistulas in Crohn's Disease: An Up-To-Date Review. Medicina (Kaunas). 2020;56(11).
210. Williams JL, Shaffer VO. Modern Management of Perianal Crohn's Disease: A Review. Am Surg. 2021;87(9):1361-7.
211. Abushamma S, Ballard DH, Smith RK, Deepak P. Multidisciplinary management of perianal Crohn's disease. Curr Opin Gastroenterol. 2021;37(4):295-305.
212. Wetwittayakhlang P, Al Khoury A, Hahn GD, Lakatos PL. The Optimal Management of Fistulizing Crohn's Disease: Evidence beyond Randomized Clinical Trials. J Clin Med. 2022;11(11).
213. Oliveira MC, Elias JB, Moraes DA, Simões BP, Rodrigues M, Ribeiro AAF, et al. A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. Hematol Transfus Cell Ther. 2021;43(1):65-86.
214. Wang R, Yao Q, Chen W, Gao F, Li P, Wu J, et al. Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies. Stem Cell Res Ther. 2021;12(1):463.
215. El-Nakeep S, Shawky A, Abbas SF, Abdel Latif O. Stem cell transplantation for induction of remission in medically refractory Crohn's disease. Cochrane Database Syst Rev. 2022;5(5):Cd013070.
216. Berthelot JM, Le Goff B, Maugars Y. Bone marrow mesenchymal stem cells in rheumatoid arthritis, spondyloarthritis, and ankylosing spondylitis: problems rather than solutions? Arthritis Res Ther. 2019;21(1):239.
217. Li YJ, Chen Z. Cell-based therapies for rheumatoid arthritis: opportunities and challenges. Ther Adv Musculoskelet Dis. 2022;14:1759720x221100294.
218. Taheri M, Eghtedarian R, Dinger ME, Ghafouri-Fard S. Dysregulation of non-coding RNAs in Rheumatoid arthritis. Biomed Pharmacother. 2020;130:110617.
219. Tsai CY, Hsieh SC, Liu CW, Lu CH, Liao HT, Chen MH, et al. The Expression of Non-Coding RNAs and Their Target Molecules in Rheumatoid Arthritis: A Molecular Basis for Rheumatoid Pathogenesis and Its Potential Clinical Applications. International journal of molecular sciences. 2021;22(11).
220. Liu H, Li R, Liu T, Yang L, Yin G, Xie Q. Immunomodulatory Effects of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Rheumatoid Arthritis. Front Immunol. 2020;11:1912.
221. Ciobanu DA, Poenariu IS, Crînguș LI, Vreju FA, Turcu-Stiolica A, Tica AA, et al. JAK/STAT pathway in pathology of rheumatoid arthritis (Review). Exp Ther Med. 2020;20(4):3498-503.
222. Sarsenova M, Issabekova A, Abisheva S, Rutskaya-Moroshan K, Ogay V, Saparov A. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. International journal of molecular sciences. 2021;22(21).
223. Lopez-Santalla M, Bueren JA, Garin MI. Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies. EBioMedicine. 2021;69:103427.
224. Lopez-Santalla M, Fernandez-Perez R, Garin MI. Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications. Cells. 2020;9(8).
225. El-Jawhari JJ, El-Sherbiny Y, McGonagle D, Jones E. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors? Front Immunol. 2021;12:643170.
226. Roudsari PP, Alavi-Moghadam S, Rezaei-Tavirani M, Goodarzi P, Tayanloo-Beik A, Sayahpour FA, et al. The Outcome of Stem Cell-Based Therapies on the Immune Responses in Rheumatoid Arthritis. Adv Exp Med Biol. 2021;1326:159-86.
227. Hwang JJ, Rim YA, Nam Y, Ju JH. Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis. Front Immunol. 2021;12:631291.
228. Prasad P, Verma S, Surbhi, Ganguly NK, Chaturvedi V, Mittal SA. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem. 2022.
229. Debreova M, Culenova M, Smolinska V, Nicodemou A, Csobonyeiova M, Danisovic L. Rheumatoid arthritis: From synovium biology to cell-based therapy. Cytotherapy. 2022;24(4):365-75.
230. Navashenaq JG, Shabgah AG, Hedayati-Moghadam M, Ariaee N, Mohammadi H, Hemmatzadeh M, et al. The role of myeloid-derived suppressor cells in rheumatoid arthritis: An update. Life Sci. 2021;269:119083.
231. Mousavi MJ, Karami J, Aslani S, Tahmasebi MN, Vaziri AS, Jamshidi A, et al. Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe. Auto Immun Highlights. 2021;12(1):3.
232. Lv X, Wang L, Zou X, Huang S. Umbilical Cord Mesenchymal Stem Cell Therapy for Regenerative Treatment of Rheumatoid Arthritis: Opportunities and Challenges. Drug Des Devel Ther. 2021;15:3927-36.
233. Miao HB, Wang F, Lin S, Chen Z. Update on the role of extracellular vesicles in rheumatoid arthritis. Expert Rev Mol Med. 2022;24:e12.
234. Brondello JM, Djouad F, Jorgensen C. Where to Stand with Stromal Cells and Chronic Synovitis in Rheumatoid Arthritis? Cells. 2019;8(10).
235. Patti F, Chisari CG, Toscano S, Arena S, Finocchiaro C, Cimino V, et al. Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. J Clin Med. 2022;11(4).
236. Rayatpour A, Farhangi S, Verdaguer E, Olloquequi J, Ureña J, Auladell C, et al. The Cross Talk between Underlying Mechanisms of Multiple Sclerosis and Epilepsy May Provide New Insights for More Efficient Therapies. Pharmaceuticals (Basel). 2021;14(10).
237. Scalabrino G. Epidermal Growth Factor in the CNS: A Beguiling Journey from Integrated Cell Biology to Multiple Sclerosis. An Extensive Translational Overview. Cell Mol Neurobiol. 2022;42(4):891-916.
238. Shokati A, Naser Moghadasi A, Nikbakht M, Sahraian MA, Mousavi SA, Ai J. A focus on allogeneic mesenchymal stromal cells as a versatile therapeutic tool for treating multiple sclerosis. Stem Cell Res Ther. 2021;12(1):400.
239. Cencioni MT, Genchi A, Brittain G, de Silva TI, Sharrack B, Snowden JA, et al. Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party. Front Immunol. 2021;12:813957.
240. Dema M, Eixarch H, Villar LM, Montalban X, Espejo C. Immunosenescence in multiple sclerosis: the identification of new therapeutic targets. Autoimmun Rev. 2021;20(9):102893.
241. Hassanshahi G, Roohi MA, Esmaeili SA, Pourghadamyari H, Nosratabadi R. Involvement of various chemokine/chemokine receptor axes in trafficking and oriented locomotion of mesenchymal stem cells in multiple sclerosis patients. Cytokine. 2021;148:155706.
242. Wens I, Janssens I, Derdelinckx J, Meena M, Willekens B, Cools N. Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies. International journal of molecular sciences. 2021;22(14).
243. Tsouki F, Williams A. Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis. Stem Cells. 2021;39(8):993-1007.
244. Jakimovski D, Awan S, Eckert SP, Farooq O, Weinstock-Guttman B. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs. 2022;36(1):45-59.
245. Scalabrino G. New Epidermal-Growth-Factor-Related Insights Into the Pathogenesis of Multiple Sclerosis: Is It Also Epistemology? Front Neurol. 2021;12:754270.
246. Förster M, Nelke C, Räuber S, Lassmann H, Ruck T, Sormani MP, et al. Nitrosative Stress Molecules in Multiple Sclerosis: A Meta-Analysis. Biomedicines. 2021;9(12).
247. Thomas AM, Barkhof F, Bulte JWM. Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment. Radiology. 2022;303(3):486-97.
248. Mehmood A, Ali W, Song S, Din ZU, Guo RY, Shah W, et al. Optical coherence tomography monitoring and diagnosing retinal changes in multiple sclerosis. Brain Behav. 2021;11(10):e2302.
249. Ben-Shalom I, Karni A, Kolb H. The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis. International journal of molecular sciences. 2021;23(1).
250. Smith JA, Nicaise AM, Ionescu RB, Hamel R, Peruzzotti-Jametti L, Pluchino S. Stem Cell Therapies for Progressive Multiple Sclerosis. Front Cell Dev Biol. 2021;9:696434.
251. Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic Advances in Multiple Sclerosis. Front Neurol. 2022;13:824926.
252. ArefNezhad R, Motedayyen H, Mohammadi A. Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review. Int J Stem Cells. 2021;14(3):241-51.
253. Gold R, Fätkenheuer G, Hartung HP, Kleinschnitz C, Marks R, Maschke M, et al. Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. Ther Adv Neurol Disord. 2021;14:17562864211019598.
254. Feller L, Khammissa RAG, Lemmer J. Is chronic ulcerative stomatitis a variant of lichen planus, or a distinct disease? J Oral Pathol Med. 2017;46(10):859-63.
255. Boccellino M, Di Stasio D, Romano A, Petruzzi M, Lucchese A, Serpico R, et al. Lichen planus: molecular pathway and clinical implications in oral disorders. J Biol Regul Homeost Agents. 2018;32(2 Suppl. 1):135-8.
256. Feily A, Yaghoobi R, Nilforoushzadeh MA. Treatment modalities of palmoplantar lichen planus: a brief review. Postepy Dermatol Alergol. 2016;33(6):411-5.
257. Gemery JM, Forauer AR, Hoffer EK. Activation of stem cell up-regulation/mobilization: a cardiovascular risk in both mice and humans with implications for liver disease, psoriasis and SLE. Vasc Health Risk Manag. 2019;15:309-16.
258. Ghafouri-Fard S, Eghtedarian R, Taheri M, Rakhshan A. The eminent roles of ncRNAs in the pathogenesis of psoriasis. Noncoding RNA Res. 2020;5(3):99-108.
259. Zenz R, Wagner EF. Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol. 2006;38(7):1043-9.
260. Paganelli A, Tarentini E, Benassi L, Kaleci S, Magnoni C. Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. Clin Exp Dermatol. 2020;45(7):824-30.
261. Sawarkar SP, Yadav V. Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis. Indian J Dermatol Venereol Leprol. 2021;87(3):333-40.
262. Lwin SM, Snowden JA, Griffiths CEM. The promise and challenges of cell therapy for psoriasis. Br J Dermatol. 2021;185(5):887-98.
263. Iizuka H, Takahashi H. Psoriasis, involucrin, and protein kinase C. Int J Dermatol. 1993;32(5):333-8.
264. Griffiths CE, Voorhees JJ. Psoriasis, T cells and autoimmunity. J R Soc Med. 1996;89(6):315-9.
265. Benhadou F, Mintoff D, Del Marmol V. Psoriasis: Keratinocytes or Immune Cells - Which Is the Trigger? Dermatology. 2019;235(2):91-100.
266. Tian D, Lai Y. The Relapse of Psoriasis: Mechanisms and Mysteries. JID Innov. 2022;2(3):100116.
267. Kaffenberger BH, Wong HK, Jarjour W, Andritsos LA. Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation. J Am Acad Dermatol. 2013;68(3):489-92.
268. Campanati A, Consales V, Orciani M, Giuliodori K, Ganzetti G, Bobyr I, et al. Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives. Psoriasis (Auckl). 2017;7:73-85.
269. Aryanian Z, Balighi K, Hatami P, Goodarzi A, Mohandesi NA, Afshar ZM. SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review. Dermatol Ther. 2022;35(5):e15430.
270. Naik PP. Stem cell therapy as a potential treatment option for psoriasis. An Bras Dermatol. 2022;97(4):471-7.
271. Owczarczyk-Saczonek A, Krajewska-Włodarczyk M, Kruszewska A, Placek W, Maksymowicz W, Wojtkiewicz J. Stem Cells as Potential Candidates for Psoriasis Cell-Replacement Therapy. International journal of molecular sciences. 2017;18(10).
272. Hou R, Li J, Niu X, Liu R, Chang W, Zhao X, et al. Stem cells in psoriasis. J Dermatol Sci. 2017;86(3):181-6.
273. Marina ME, Roman, II, Constantin AM, Mihu CM, Tătaru AD. VEGF involvement in psoriasis. Clujul Med. 2015;88(3):247-52.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2022 PreferPub and Kindle
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Since making research freely available supports a greater global exchange of knowledge, PreferPub provides immediate open access to its published books under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (CC BY-NC 4.0). This license allows others to share, copy, and redistribute the material in any medium or format, as well as adapt, remix, transform, and build upon the material, as long as the use is non-commercial and appropriate credit is given to the original work.
